Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

AI-Based Medical Data Analysis for Differentiating Inflammatory vs Degenerative Joint Diseases in Elderly Patients

NCT07153315 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-09-01
Last updated
2025-09-03

Condition(s) studied

Arthritis, Rheumatoid (RA)

Study summary

This study aims to evaluate the diagnostic accuracy of AI-assisted imaging analysis in differentiating between inflammatory and degenerative joint diseases in elderly patients. The performance of AI-based analysis will be compared with radiologists' assessments to determine its reliability in clinical practice. In addition, the study will explore imaging features most predictive of each disease type using advanced machine learning techniques. Finally, the feasibility of implementing AI tools in the routine management of geriatric musculoskeletal disorders will be assessed.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion criteria : 1. Age ≥ 60 years 2. Clinical suspicion or confirmed diagnosis of inflammatory joint disease (e.g., rheumatoid arthritis, psoriatic arthritis) or degenerative joint disease (e.g., osteoarthritis) 3. Availability of relevant musculoskeletal imaging (X-rays, MRI, or ultrasound) suitable for AI-based analysis 4. Ability to provide informed consent or have a legal representative consent on behalf of the Exclusion criteria: 1. History of recent joint trauma (within the last 6 months) or previous joint surgery affecting the studied sites 2. Presence of bone or joint malignancy (primary or metastatic) 3. Diagnosis of overlapping rheumatologic syndromes or mixed pathology (e.g., RA with concurrent gout, or OA with inflammatory overlap) 4. Inadequate imaging quality or absence of required imaging modalities 5. Inability or unwillingness to provide informedconsent

Primary outcome measure(s)

  • Diagnostic accuracy of AI system — Within 12 months from baseline assessment.
    Sensitivity, specificity, and AUC of AI algorithm for differentiating inflammatory from degenerative joint diseases, using imaging data, compared to expert rheumatologist diagnosis

Trial sites (1)

FacilityCityRegionStatus
Assiut University Hospital Asyut Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07153315 on ClinicalTrials.gov ↗ ← All trials in Egypt